





29th EADV Congress, 29.-31.10.2020, EADVirtual

Pharmacovigilance of systemic antipsoriatic treatment: Results from more than 17,000 patient years in the German Psoriasis Registry PsoBest

Mrowietz U, Kühl L, Sorbe C, Rustenbach SJ, von Kiedrowski R, Augustin M









German Psoriasis Registry PsoBest

- Non-interventional, multicenter patient registry
- Adult patients with moderate to severe psoriasis
- Observation regardless of further treatment course



initiated 2008



² 550 registry sites



~ 14,000 patients



10-15 years observation





Figure: Number of registry sites per post code area troughout Germany









Event assessment and assignment

۲

The second secon	THE INC				
Bert and my server as	and the second se		in the second labor		Padlingt
	Contraction of the	Part & days	-		No. of Lot of Lo
Contract of the local division of the local	Contract of the local division of the local	and a state of the local division of the loc	0119	ne rue	
Company of the local division of the local d	**************************************	the same	Time and		
	Contraction (- itters	Addate in the local division of the local di
Balance of Street			11000	11=	
1	100	7258445		1	
		Particilla.	1111111	1000	of the local division of the local divisiono
		particular in the second			
A second distance of the second distance of t	and in	miller	La sta da da		
Conception Name		and in case of the local division of the loc	No. of Lot of Lo	4	
				- second in	All and a local division of the local divisi

Non-serious adverse events

- Without inpatient hospitalisation
- Documentation via regular visit
 - e.g. new comorbidity, injuries



manufact ()) ())	deres d	Assessed in the local	
manner hiddanial		manual Asian	in the last
Thereis a constrained			
	and the second second		
and Designation	and the other distances in the local distance		
Sector Manager	and the second second	Name of Street and Street	
1.12	10. 1 2		1
States of Lot of	The I berry I at	and of Taxaban	1000 1100
Special Designed		and the second second	
and interview			-
Sector Contractor			
-		_	
Address of the local division of the local d	And the Party of the	Concepts of the	and some
item in the	COLUMN DWG 1	tion of the local division of the local divi	
		and the second second	1 1010.
The state of the s		and so its and	1 -
	a to the second s		1.000
	r 1		
there are a set	ALC: NOT THE OWNER OF THE		100
1002		_	
TO KANNING			
	_	-	
and international little			
Second St.		Taxable In	-
from to	1.1	-	


0

serious adverse events

in Dermatology

- With inpatient hospitalisation
- Documentation via special form and rapid report
- e.g. MI, malignacies, death









in Dermatology






Figure: Prospective exposure time in PsoBest, n= 9,748





in Dermatology



Patient Baseline

Biologics, n= 3,888	n	mean	median	range	
Age [years]	3,888	47.7	48.0	18 - 89	61.4 % male
Duration of illness [years]	3,552	20.1	18.0	0 - 70	54.2 % nail psoria
PASI	3,796	16.1	14.1	0 - 66.6	41.5 % psoriatic art
DLQI	3,704	12.4	12.0	0 - 30	
BMI	3,837	29.0	28.1	14.9 - 57.9	
Non-biologics, n= 6,251	n	mean	median	range	
Age [years]	6,251	. 47.6	48.0	18 - 92	57.3 % male
Duration of illness [years]	5,688	3 16.2	13.0	0 - 76	46.1 % nail psoria
PASI	6,108	3 14.4	12.5	0 - 69.6	26.4 % psoriatic art
DLQI	5,957	11.2	11.0	0 - 30	
BMI	6,188	28.4	27.5	14.7 - 67.3	

Combined treatment possible; Psoriasis Area and Severity Index 0= no to 72= maximum severity, Body Surface Area 0 to 100 %, Dermatology Life Quality Index 0= no to 30= maximum impairment





in Dermatology

German Center for Health Services Research



Non-serious adverse events in non-biologic treatment

Rank	System organ class	events	patients	% patients	Patient rate*
1	Gastrointestinal disorders	1950	1079	17.26	11.80 (11.10-12.52)
2	General disorders and administration site conditions	1296	930	14.88	10.17 (9.52-10.84)
3	Skin and subcutaneous tissue disorders	630	457	7.31	5.00 (4.55-5.48)
4	Infections and infestations	667	456	7.29	4.98 (4.54-5.46)
5	Investigations	465	335	5.36	3.66 (3.28-4.08)
6	Nervous system disorders	339	262	4.19	2.86 (2.53-3.23)
7	Musculoskeletal and connective tissue disorders	311	242	3.87	2.65 (2.32-3.00)
8	Blood and lymphatic system disorders	295	214	3.42	2.34 (2.04-2.67)
9	Vascular disorders	215	187	2.99	2.04 (1.76-2.36)
10	Psychiatric disorders	165	134	2.14	1.46 (1.23-1.73)

* Patients cumulative/100 Patient Years (95% confidence interval), as-exposed analysis





in Dermatology

German Center for Health Services Research




Non-serious adverse events in biologic treatment

Rank	System organ class	events	patients	% patients	Patient rate*
1	General disorders and administration site conditions	1048	724	18.62	9.22 (8.56-9.91)
2 🥚	Infections and infestations	898	539	13.86	6.86 (6.30-7.47)
3	Musculoskeletal and connective tissue disorders	332	248	6.38	3.16 (2.78-3.58)
4 🥘	Gastrointestinal disorders	297	207	5.32	2.64 (2.29-3.02)
5 🥚	Skin and subcutaneous tissue disorders	252	194	4.99	2.47 (2.13-2.84)
6 🥚	Investigations	197	153	3.93	1.95 (1.65-2.28)
7 🦲	Nervous system disorders	159	128	3.29	1.63 (1.36-1.94)
8	Respiratory, thoracic and mediastinal disorders	154	124	3.19	1.58 (1.31-1.88)
9 🥘	Vascular disorders	116	105	2.70	1.34 (1.09-1.62)
10	Psychiatric disorders	108	90	2.31	1.15 (0.92-1.41)
•••					
16 🥚	Blood and lymphatic system disorders	41	35	0.90	0.45 (0.31-0.62)
* Pati	ents cumulative/100 Patient Years	Significan	tly higher 🔴	patient rate com	pared to non-biologics

(95% confidence interval), as-exposed analysis

lower







German Center for Health Services Research in Dermatology








Figure: Standardized patient rates per 100 patient years exposed to biologics and non-biologics (as-exposed analysis)



German Center for Health Services Research in Dermatology

CVderm




All-cause death and malignancies

	Biologics			
	All cause death	Malignancies		
male	0.57 (0.38-0.83)	0.93 (0.68-1.25)		
female	0.51 (0.28-0.86)	1.25 (0.87-1.75)		
total	0.55 (0.40-0.75)	1.05 (0.83-1.31)		

Non-Biologics

	All cause death	Malignancies
male	0.83 (0.61-1.11)	1.02 (0.77-1.32)
female	0.45 (0.26-0.72)	1.21 (0.89-1.62)
total	0.67 (0.52-0.86)	1.10 (0.89-1.33)



patient-rates per 100 PY

Figure: Standardized patient rates per 100 patient years ever exposed to biologics and non-biologics (ever-exposed analysis)









Conclusions

- Specific differences in non-serious adverse events, predominantly well known
- differences in serious adverse events < 1 patient/100 patient years

 Registry data shows the high safety of systemic psoriasis therapy in Germany









University Medical Center C Sorbe, Pharmacovigilance of systemic antipsoriatic treatment



in Dermatology





The registry is financed by the German Dermatologists (DDG and BVDD), as well as through pooled funds from scientific cooperation with pharmaceutical companies.

